Another OTC product sale for Sanofi, this one to Hypera Pharma
Japanese company Takeda Pharmaceutical has completed the previously announced sale of select over-the-counter (OTC) and non-core assets in Latin America to Hypera Pharma for $825m.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (“Hypera Pharma”) for a total value of $825 million USD. This divestment agreement was first announced in March 2020.